Resverlogix Corp. News Releases

Resverlogix Corp. Announces Issuance of MCTO by ASC

Thu, 02 Apr 2026 07:15:00 -0400

Calgary, Alberta--(Newsfile Corp. - April 2, 2026) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") today announces the issuance of a management cease trade order ("MCTO") by the Alberta Securities Commission (the "ASC") under National Policy 12-203 - Management Cease Trade Orders ("NP 12-203"), following an application made by the Company, and first announced on March 17, 2026 (the "Original Announcement"). The MCTO relates to Resverlogix's default on the prescribed deadline of...

Resverlogix Corp. Provides Bi-Weekly MCTO Status Update

Tue, 31 Mar 2026 19:09:00 -0400

Calgary, Alberta--(Newsfile Corp. - March 31, 2026) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") is providing an update on the management cease trade order ("MCTO") application it made to the Alberta Securities Commission (the "ASC") under National Policy 12-203 - Management Cease Trade Orders ("NP 12-203"). The application remains under review, and no decision has yet been made by the ASC. The Company announced on March 17, 2026 (the "Original Announcement") that it had been...

Resverlogix Announces Delay in Filing of Annual Financial Statements, AIF, and MD&A

Tue, 17 Mar 2026 22:49:00 -0400

Calgary, Alberta--(Newsfile Corp. - March 17, 2026) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") today announces that because of delays in the completion of its year-end audit, the Company anticipates it will be unable to meet the prescribed deadline of March 31, 2026 for filing of the following continuous disclosure documents (collectively, the "Annual Filings"): Annual Audited Financial Statements, Annual Information Form, and Management Discussion & Analysis for the year...

Resverlogix Closes $2.8 Million Shares-for-Interest Private Placement

Wed, 18 Feb 2026 19:00:00 -0500

Calgary, Alberta--(Newsfile Corp. - February 18, 2026) - Resverlogix Corp. (TSX: RVX) ("Resverlogix") announced today that it has closed a $2.8 million shares-for-interest private placement with an immediate family member (the "Subscriber") of Resverlogix's Chairman and CEO. Under the terms of the shares-for-interest transaction, the Subscriber subscribed for 28,000,000 common shares at CAD$0.10 per share for aggregate proceeds of CAD$2.8 million. After giving effect to the transaction, the...

Resverlogix Appoints Bradley Glass to Board of Directors

Tue, 18 Nov 2025 17:15:00 -0500

Calgary, Alberta--(Newsfile Corp. - November 18, 2025) - Resverlogix Corp. (TSX: RVX) ("Resverlogix", or the "Company") today announces the appointment of Mr. Bradley Glass, J.D. as a member of the Company's board of directors.Mr. Glass has served as the General Counsel of Hepalink USA, Inc. and its subsidiaries ("Hepalink") for the past four years. In that role, Mr. Glass is responsible for managing all of Hepalink's U.S. legal issues. Prior to joining Hepalink, Mr. Glass was in private law...

Resverlogix Announces Voting Results from the 2025 Meeting of Shareholders

Mon, 30 Jun 2025 17:31:00 -0400

Calgary, Alberta--(Newsfile Corp. - June 30, 2025) - Resverlogix Corp. (TSX: RVX) ("Resverlogix", or the "Corporation") today held its Annual Meeting of Shareholders (the "Meeting") in Calgary, Alberta. During business proceedings at the Meeting, shareholders elected four (4) Board members until the next annual meeting. The voting results of shares represented at the Meeting for individual directors were as follows:Votes ForVotes WithheldPercent ForPercent WithheldDonald J....

Numerous Independent Groups Presented Data that Supports Apabetalone's Potential Cardioprotective Benefits at European Society of Cardiology Congress 2024

Tue, 03 Sep 2024 10:15:00 -0400

Numerous GLP-1 RA and SGLT2i presentations touted their clinical results, providing continued excitement for our BETonMACE program, which observed a non-prespecified 63% reduction in MACE and heart failure hazard among patients taking next-generation glucose lowering drugs Calgary, Alberta--(Newsfile Corp. - September 3, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or "the Company") today announced its presentation at the European Society of Cardiology ("ESC") Congress 2024 in London, UK...

Resverlogix Announces Voting Results from the 2024 Meeting of Shareholders and Closing of Debenture Extension

Wed, 31 Jul 2024 18:30:00 -0400

Calgary, Alberta--(Newsfile Corp. - July 31, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix", or the "Corporation") today held its Annual & Special Meeting of Shareholders (the "Meeting") in Calgary, Alberta. During business proceedings at the Meeting, shareholders elected four (4) Board members until the next annual meeting. The voting results of shares represented at the Meeting for individual directors were as follows:Votes ForVotes WithheldPercent ForPercent WithheldDonald J....

Resverlogix Provides Update Regarding Two-Year Extension of Debenture and Elimination of Conversion Privileges

Tue, 16 Jul 2024 07:15:00 -0400

Calgary, Alberta--(Newsfile Corp. - July 16, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announced it has entered into definitive transaction documents for the two-year extension of the Company's US$6.0 million secured convertible debenture (the "Debenture") with Shenzhen Hepalink Pharmaceutical Group Co., Ltd. ("Hepalink") (and payment of accrued interest thereon), extending the maturity date to May 13, 2026. As previously announced, in connection with the extension,...

Resverlogix Announces Updated Annual and Special Meeting of Shareholders

Tue, 28 May 2024 17:00:00 -0400

Calgary, Alberta--(Newsfile Corp. - May 28, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announced today that its Annual and Special Meeting of Shareholders (the "Meeting") will be held on Wednesday, July 31, 2024, commencing at approximately 1:00 pm (MT), as opposed to as previously scheduled for June 27, 2024.A Notice of Meeting and Management Information Circular, containing the matters to be considered at the Meeting, will be delivered to shareholders and filed on...